List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7531930/publications.pdf

Version: 2024-02-01

13771 10986 22,894 386 71 129 citations h-index g-index papers 400 400 400 22784 all docs citing authors docs citations times ranked

#	ARTICLE	IF	CITATIONS
1	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. International Journal of Gynecological Cancer, 2022, 32, 560-565.	2.5	4
2	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	2.5	2
3	Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1091.2021.	2.5	1
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
5	Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment) Tj $ETQq1\ 1\ 0$.	78 4. 314 rg	gBTI‡Overlo <mark>ck</mark>
6	The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes and Endocrinology,the, 2022, 10, 120-128.	11.4	79
7	Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older. Journal of the National Cancer Institute, 2022, 114, 878-884.	6.3	3
8	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. Journal of Clinical Oncology, 2022, , JCO2102108.	1.6	3
9	Germline BRCA variants, lifestyle and ovarian cancer survival. Gynecologic Oncology, 2022, , .	1.4	2
10	OUP accepted manuscript. Journal of the National Cancer Institute, 2022, , .	6.3	0
11	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. Cancers, 2022, 14, 1954.	3.7	3
12	Methodological considerations in D-health cancer mortality results – Authors' reply. Lancet Diabetes and Endocrinology,the, 2022, 10, 307-308.	11.4	0
13	Dietary Practices After Primary Treatment for Ovarian Cancer: A Qualitative Analysis From the OPAL Study. Journal of the Academy of Nutrition and Dietetics, 2022, 122, 1607-1628.e12.	0.8	5
14	The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial. British Journal of Dermatology, 2022, 187, 667-675.	1.5	4
15	Vitamin D Supplementation and Antibiotic Use in Older Australian Adults: An Analysis of Data From the D-Health Trial. Journal of Infectious Diseases, 2022, 226, 949-957.	4.0	4
16	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
17	Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2 </i> as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	3.2	26
18	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	6.3	8

#	Article	IF	CITATIONS
19	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
20	Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using populationâ€based cohort studies and twoâ€sample Mendelian randomization analyses. International Journal of Cancer, 2021, 148, 1338-1350.	5.1	9
21	Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. International Journal of Cancer, 2021, 148, 1608-1615.	5.1	24
22	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 229-232.	2.5	14
23	Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer, 2021, 148, 2068-2078.	5.1	14
24	Reproductive factors, hormone use and melanoma risk: an Australian prospective cohort study. British Journal of Dermatology, 2021, 184, 361-363.	1.5	5
25	A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nature Communications, 2021, 12, 246.	12.8	39
26	The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 69-81.	11.4	41
27	Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 927-935.	2.5	10
28	Hysterectomy and Risk of Breast, Colorectal, Thyroid, and Kidney Cancer – an Australian Data Linkage Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 904-911.	2.5	9
29	Dietitian encounters after treatment for ovarian cancer. Journal of Human Nutrition and Dietetics, 2021, 34, 1053-1063.	2.5	6
30	Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees. Contemporary Clinical Trials, 2021, 104, 106347.	1.8	16
31	Statin use and survival among women with ovarian cancer: an Australian national data-linkage study. British Journal of Cancer, 2021, 125, 766-771.	6.4	13
32	Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: Results from an Australian record-linkage study. Gynecologic Oncology, 2021, 161, 858-863.	1.4	3
33	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
34	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18
35	Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. Gynecologic Oncology, 2021, 162, 461-468.	1.4	8
36	Vitamin D supplementation and risk of falling: outcomes from the randomized, placeboâ€controlled Dâ€Health Trial. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1428-1439.	7.3	27

#	Article	IF	CITATIONS
37	Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. Gynecologic Oncology, 2021, 163, 398-407.	1.4	5
38	680NSAID use and ovarian cancer survival. International Journal of Epidemiology, 2021, 50, .	1.9	O
39	647Use of menopausal hormone therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Epidemiology, 2021, 50, .	1.9	O
40	The future excess fraction of cancer due to lifestyle factors in Australia. Cancer Epidemiology, 2021, 75, 102049.	1.9	1
41	Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology, $2021, , .$	1.4	5
42	The influence of birth cohort and calendar period on global trends in ovarian cancer incidence. International Journal of Cancer, 2020, 146, 749-758.	5.1	40
43	Patterns of, and barriers to supportive care needs assessment and provision for Australian women with gynecological cancer and their caregivers: a mixed-methods study of clinical practice. Palliative and Supportive Care, 2020, 18, 170-177.	1.0	15
44	Dietary inflammatory index, risk and survival among women with endometrial cancer. Cancer Causes and Control, 2020, 31, 203-207.	1.8	9
45	The proportion of cancers attributable to social deprivation: A population-based analysis of Australian health data. Cancer Epidemiology, 2020, 67, 101742.	1.9	4
46	Insomnia and its association with quality of life in women with ovarian cancer. Gynecologic Oncology, 2020, 158, 760-768.	1.4	17
47	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case–control studies. European Journal of Epidemiology, 2020, 35, 1025-1042.	5.7	2
48	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	2.7	12
49	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecologic Oncology, 2020, 159, 179-186.	1.4	20
50	Hysterectomy with and without oophorectomy and all-cause and cause-specific mortality. American Journal of Obstetrics and Gynecology, 2020, 223, 723.e1-723.e16.	1.3	34
51	Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. Gynecologic Oncology, 2020, 158, 47-53.	1.4	6
52	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	1.2	85
53	Estimating the costs of genomic sequencing in cancer control. BMC Health Services Research, 2020, 20, 492.	2.2	18
54	A healthy lifestyle and survival among women with ovarian cancer. International Journal of Cancer, 2020, 147, 3361-3369.	5.1	16

#	Article	IF	CITATIONS
55	Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology, 2020, 6, e200421.	7.1	78
56	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	1.4	15
57	Generating high-quality data abstractions from scanned clinical records: text-mining-assisted extraction of endometrial carcinoma pathology features as proof of principle. BMJ Open, 2020, 10, e037740.	1.9	7
58	Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer. Scientific Reports, 2020, 10, 3621.	3.3	33
59	Body mass index and height and risk of cutaneous melanoma: Mendelian randomization analyses. International Journal of Epidemiology, 2020, 49, 1236-1245.	1.9	21
60	Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. Gynecologic Oncology, 2020, 157, 678-685.	1.4	29
61	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
62	The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer. European Journal of Nutrition, 2019, 58, 1747-1756.	3.9	19
63	Response to van Diest, Zweemer, and Piek. Journal of the National Cancer Institute, 2019, 111, 1362-1362.	6.3	0
64	"l am not a statistic―ovarian cancer survivors' views of factors that influenced their long-term survival. Gynecologic Oncology, 2019, 155, 461-467.	1.4	19
65	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
66	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	1.9	22
67	A systematic literature review of trials of survivorship interventions for women with gynaecological cancer and their caregivers. European Journal of Cancer Care, 2019, 28, e13057.	1.5	34
68	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	1.8	16
69	A randomized placebo-controlled trial of vitamin D supplementation for reduction of mortality and cancer: Statistical analysis plan for the D-Health Trial. Contemporary Clinical Trials Communications, 2019, 14, 100333.	1.1	22
70	The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study. Journal of the National Cancer Institute, 2019, 111, 1097-1103.	6.3	17
71	The impact of reducing alcohol consumption in Australia: An estimate of the proportion of potentially avoidable cancers 2013–2037. International Journal of Cancer, 2019, 145, 2944-2953.	5.1	8
72	Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals of Oncology, 2019, 30, 310-316.	1.2	28

#	Article	IF	Citations
73	The impact of changing the prevalence of overweight/obesity and physical inactivity in Australia: An estimate of the proportion of potentially avoidable cancers 2013–2037. International Journal of Cancer, 2019, 144, 2088-2098.	5.1	20
74	A comprehensive gene–environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	5.1	12
75	"l Wasn't Gonna Let It Stop Me― Exploring Women's Experiences of Getting Through Chemotherapy for Ovarian Cancer. Cancer Nursing, 2019, 42, E31-E38.	1.5	10
76	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
77	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
78	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
79	Ovarian cancer risk, <scp>ALDH</scp> 2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. Cancer Science, 2018, 109, 435-445.	3.9	10
80	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
81	The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. Gynecologic Oncology, 2018, 150, 99-105.	1.4	49
82	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal of Epidemiology, 2018, 47, 460-472.	1.9	33
83	Short-term cancer risks associated with oral contraceptives are balanced by longer term benefits. BMJ Evidence-Based Medicine, 2018, 23, 115-116.	3 . 5	0
84	Risk Stratification for Melanoma: Models Derived and Validated in a Purpose-Designed Prospective Cohort. Journal of the National Cancer Institute, 2018, 110, 1075-1083.	6.3	50
85	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. American Journal of Epidemiology, 2018, 187, 366-377.	3.4	8
86	Hormonal and reproductive factors and incidence of basal cell carcinoma and squamous cell carcinoma in a large, prospective cohort. Journal of the American Academy of Dermatology, 2018, 78, 615-618.e2.	1,2	8
87	Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. International Journal of Cancer, 2018, 142, 460-469.	5.1	6
88	A systematic literature review of the prevalence of and risk factors for supportive care needs among women with gynaecological cancer and their caregivers. Supportive Care in Cancer, 2018, 26, 701-710.	2.2	47
89	ER and PR expression and survival after endometrial cancer. Gynecologic Oncology, 2018, 148, 258-266.	1.4	49
90	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 174-182.	2.5	20

#	Article	IF	Citations
91	Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynchâ€associated cancers—A populationâ€based analysis. Cancer Medicine, 2018, 7, 6411-6422.	2.8	9
92	Smoking and Cutaneous Melanoma: Findings from the QSkin Sun and Health Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 874-881.	2.5	20
93	The Imperative for a Triumph-Over-Tragedy Story in Women's Accounts of Undergoing Chemotherapy for Ovarian Cancer. Qualitative Health Research, 2018, 28, 1759-1768.	2.1	8
94	Endometrial cancer risk and survival by tumor MMR status. Journal of Gynecologic Oncology, 2018, 29, e39.	2.2	34
95	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
96	Does aspirin have a role in management of ovarian cancer?. Lancet Oncology, The, 2018, 19, 1011-1012.	10.7	2
97	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
98	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Supportive Care in Cancer, 2018, 26, 4133-4142.	2.2	29
99	How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. International Journal of Cancer, 2018, 142, 691-701.	5.1	71
100	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT) Journal of Clinical Oncology, 2018, 36, 10062-10062.	1.6	2
101	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis Journal of Clinical Oncology, 2018, 36, 10081-10081.	1.6	4
102	The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis Journal of Clinical Oncology, 2018, 36, 155-155.	1.6	0
103	The Ovarian cancer Prognosis And Lifestyle (OPAL) study Journal of Clinical Oncology, 2018, 36, 88-88.	1.6	2
104	When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer Journal of Clinical Oncology, 2018, 36, 172-172.	1.6	0
105	Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort Journal of Clinical Oncology, 2018, 36, 5568-5568.	1.6	0
106	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	5.1	25
107	Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future. Cancer Causes and Control, 2017, 28, 365-370.	1.8	22
108	Breastfeeding and Endometrial Cancer Risk. Obstetrics and Gynecology, 2017, 129, 1059-1067.	2.4	52

#	Article	IF	CITATIONS
109	Pre-diagnosis diet and survival after a diagnosis of ovarian cancer. British Journal of Cancer, 2017, 116, 1627-1637.	6.4	42
110	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
111	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	6.4	13
112	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	1.8	28
113	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2017, 28, 459-468.	1.8	20
114	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. American Journal of Epidemiology, 2017, 185, 8-20.	3.4	61
115	Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012. Journal of the National Cancer Institute, 2017, 109, .	6.3	18
116	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic Oncology, 2017, 147, 381-387.	1.4	30
117	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
118	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	2.5	10
119	Epidemiology of epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 3-14.	2.8	638
120	Ovarian cancer study dropouts had worse healthâ€related quality of life and psychosocial symptoms at baseline and over time. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e381-e388.	1.1	10
121	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
122	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	1.8	7
123	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
124	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	2.9	17
125	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. Supportive Care in Cancer, 2016, 24, 2627-2634.	2.2	15
126	A Model to Predict the Risk of Keratinocyte Carcinomas. Journal of Investigative Dermatology, 2016, 136, 1247-1254.	0.7	31

#	Article	IF	Citations
127	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1114-1124.	2.5	32
128	The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer. Contemporary Clinical Trials, 2016, 48, 83-90.	1.8	103
129	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
130	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	21.4	77
131	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
132	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	2.5	64
133	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
134	Association between family cancer history and risk of pancreatic cancer. Cancer Epidemiology, 2016, 45, 145-150.	1.9	17
135	Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes and Control, 2016, 27, 1457-1464.	1.8	18
136	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk. Obstetrical and Gynecological Survey, 2016, 71, 528-530.	0.4	0
137	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
138	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	3.1	62
139	Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	2.5	10
140	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	1,9	20
141	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
142	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer – a population-based study. Acta Oncológica, 2016, 55, 226-233.	1.8	15
143	Effect of vitamin D supplementation on selected inflammatory biomarkers in older adults: a secondary analysis of data from a randomised, placebo-controlled trial. British Journal of Nutrition, 2015, 114, 693-699.	2.3	31
144	Intrauterine devices and endometrial cancer risk: A pooled analysis of the <scp>E</scp> pidemiology of <scp>E</scp> ndometrial <scp>C</scp> ancer <scp>C</scp> onsortium. International Journal of Cancer, 2015, 136, E410-22.	5.1	54

#	Article	IF	Citations
145	Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives. Australian and New Zealand Journal of Public Health, 2015, 39, 441-445.	1.8	16
146	Cancers in Australia in 2010 attributable to inadequate consumption of fruit, nonâ€starchy vegetables and dietary fibre. Australian and New Zealand Journal of Public Health, 2015, 39, 422-428.	1.8	32
147	Cancers in Australia in 2010 attributable to the consumption of red and processed meat. Australian and New Zealand Journal of Public Health, 2015, 39, 429-433.	1.8	23
148	Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy. Australian and New Zealand Journal of Public Health, 2015, 39, 434-440.	1.8	11
149	Cancers in Australia in 2010 attributable to the consumption of alcohol. Australian and New Zealand Journal of Public Health, 2015, 39, 408-413.	1.8	21
150	Cancers in Australia in 2010 attributable to total breastfeeding durations of 12 months or less by parous women. Australian and New Zealand Journal of Public Health, 2015, 39, 418-421.	1.8	6
151	Cancers in Australia in 2010 attributable to overweight and obesity. Australian and New Zealand Journal of Public Health, 2015, 39, 452-457.	1.8	36
152	Cancers in Australia in 2010 attributable to modifiable factors: introduction and overview. Australian and New Zealand Journal of Public Health, 2015, 39, 403-407.	1.8	35
153	Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions. Australian and New Zealand Journal of Public Health, 2015, 39, 477-484.	1.8	93
154	Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. American Journal of Clinical Nutrition, 2015, 102, 109-114.	4.7	48
155	Occupational exposure toN-nitrosamines and pesticides and risk of pancreatic cancer. Occupational and Environmental Medicine, 2015, 72, 678-683.	2.8	25
156	Cancers in Australia in 2010 attributable to tobacco smoke. Australian and New Zealand Journal of Public Health, 2015, 39, 464-470.	1.8	29
157	Cancers in Australia in 2010 attributable to insufficient physical activity. Australian and New Zealand Journal of Public Health, 2015, 39, 458-463.	1.8	21
158	Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecologic Oncology, 2015, 136, 87-93.	1.4	100
159	Environmental (nongenetic) factors in gynecological cancers: update and future perspectives. Future Oncology, 2015, 11, 295-307.	2.4	25
160	Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet, The, 2015, 385, 1835-1842.	13.7	349
161	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
162	Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiology, 2015, 39, 196-199.	1.9	19

#	Article	IF	CITATIONS
163	Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal of Cancer, 2015, 112, 925-933.	6.4	41
164	Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2015, 113, 817-826.	6.4	111
165	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
166	Prevalence, predictors, and correlates of supportive care needs among women 3–5Âyears after a diagnosis of endometrial cancer. Supportive Care in Cancer, 2015, 23, 1205-1214.	2.2	39
167	Association between Helicobacter pylori and pancreatic cancer risk: a meta-analysis. Cancer Causes and Control, 2015, 26, 1027-1035.	1.8	61
168	Incidence, Risk Factors, and Estimates of a Woman's Risk for Developing Secondary Lower Limb Lymphedema and Lymphedema-Specific Supportive Care Needs in Women Treated for Endometrial Cancer. Obstetrical and Gynecological Survey, 2015, 70, 176-177.	0.4	3
169	Women's Perceptions of Their Lifestyle and Quality of Life Several Years After a Diagnosis of Endometrial Cancer. Cancer Nursing, 2015, 38, E21-E28.	1.5	10
170	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
171	Independent Validation of Six Melanoma Risk Prediction Models. Journal of Investigative Dermatology, 2015, 135, 1377-1384.	0.7	33
172	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
173	Environmental (nongenetic) factors in gynecological cancers: update and future perspectives. Future Oncology, 2015, 11, 295-307.	2.4	1
174	Survival of Australian women with invasive epithelial ovarian cancer: a populationâ€based study. Medical Journal of Australia, 2014, 201, 283-288.	1.7	56
175	A case-control study of glycemic index, glycemic load and dietary fiber intake and risk of adenocarcinomas and squamous cell carcinomas of the esophagus: the Australian Cancer Study. BMC Cancer, 2014, 14, 877.	2.6	19
176	Reply to J. Moline et al. Journal of Clinical Oncology, 2014, 32, 2278-2279.	1.6	5
177	Dietary phyto-oestrogens and the risk of ovarian and endometrial cancers: findings from two Australian case–control studies. British Journal of Nutrition, 2014, 111, 1430-1440.	2.3	22
178	Environmental, Personal, and Genetic Determinants of Response to Vitamin D Supplementation in Older Adults. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1332-E1340.	3.6	56
179	The return to work experiences of middle-aged Australian workers diagnosed with colorectal cancer: a matched cohort study. BMC Public Health, 2014, 14, 963.	2.9	43
180	Quality of Life and Treatment Response Among Women With Platinum-Resistant Versus Platinum-Sensitive Ovarian Cancer Treated for Progression. Obstetrical and Gynecological Survey, 2014, 69, 257-259.	0.4	0

#	Article	IF	Citations
181	Quality of life of women with lower limb swelling or lymphedema 3–5years following endometrial cancer. Gynecologic Oncology, 2014, 133, 314-318.	1.4	56
182	Cigarette smoking and pancreatic cancer risk: More to the story than just pack-years. European Journal of Cancer, 2014, 50, 997-1003.	2.8	31
183	Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis. Gynecologic Oncology, 2014, 132, 130-136.	1.4	11
184	Tumor Mismatch Repair Immunohistochemistry and DNA <i>MLH1</i> Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. Journal of Clinical Oncology, 2014, 32, 90-100.	1.6	195
185	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	6.3	186
186	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
187	Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. Cancer Epidemiology, 2014, 38, 576-582.	1.9	18
188	Predictors of sexual well-being after endometrial cancer: results of a national self-report survey. Supportive Care in Cancer, 2014, 22, 2715-2723.	2.2	22
189	Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 2014, 132, 690-697.	1.4	92
190	Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecologic Oncology, 2014, 132, 566-572.	1.4	25
191	Serum HE4 as a prognostic marker in endometrial cancer — A population based study. Gynecologic Oncology, 2014, 132, 159-165.	1.4	86
192	Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 2014, 133, 16-22.	1.4	47
193	Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. American Journal of Clinical Nutrition, 2014, 99, 156-161.	4.7	40
194	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer, 2013, 13, 28.	2.6	28
195	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 2013, 131, 8-14.	1.4	55
196	Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. European Journal of Nutrition, 2013, 52, 705-715.	3.9	46
197	Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 2013, 130, 162-168.	1.4	43
198	Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 2013, 132, 2876-2883.	5.1	26

#	Article	IF	Citations
199	Has the association between hysterectomy and ovarian cancer changed over time? A systematic review and meta-analysis. European Journal of Cancer, 2013, 49, 3638-3647.	2.8	33
200	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study. Gynecologic Oncology, 2013, 129, 310-317.	1.4	30
201	Association between ultraviolet radiation, skin sun sensitivity and risk of pancreatic cancer. Cancer Epidemiology, 2013, 37, 886-892.	1.9	28
202	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	1.6	613
203	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes and Control, 2013, 24, 989-1004.	1.8	84
204	Predicting vitamin D deficiency in older Australian adults. Clinical Endocrinology, 2013, 79, 631-640.	2.4	28
205	Aspirin, nonsteroidal antiâ€inflammatory drugs, paracetamol and risk of endometrial cancer: A case–control study, systematic review and metaâ€analysis. International Journal of Cancer, 2013, 132, 1146-1155.	5.1	64
206	Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. European Journal of Cancer, 2013, 49, 2717-2726.	2.8	57
207	High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecologic Oncology, 2013, 128, 327-334.	1.4	68
208	Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prevention Research, 2013, 6, 811-821.	1.5	77
209	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	3.1	26
210	Changes in supportive care needs after firstâ€line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs. Psycho-Oncology, 2013, 22, 1565-1571.	2.3	80
211	Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 429-437.	2.5	52
212	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	2.5	54
213	Predicting positive and negative impacts of cancer among longâ€term endometrial cancer survivors. Psycho-Oncology, 2013, 22, 1963-1971.	2.3	27
214	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
215	Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population. International Journal of Cancer, 2013, 133, 214-224.	5.1	40
216	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589.	1.9	146

#	Article	IF	CITATIONS
217	Obesity and Gynecologic Cancer Etiology and Survival. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e222-e228.	3.8	25
218	Obesity and Gynecologic Cancer Etiology and Survival. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e222-e228.	3.8	10
219	Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies. PLoS Medicine, 2012, 9, e1001200.	8.4	166
220	Dietary patterns and risk of oesophageal cancers: a population-based case–control study. British Journal of Nutrition, 2012, 107, 1207-1216.	2.3	23
221	Cohort profile: The QSkin Sun and Health Study. International Journal of Epidemiology, 2012, 41, 929-929i.	1.9	128
222	Association between Ambient Ultraviolet Radiation and Risk of Epithelial Ovarian Cancer. Cancer Prevention Research, 2012, 5, 1330-1336.	1.5	13
223	Recruitment and Results of a Pilot Trial of Vitamin D Supplementation in the General Population of Australia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4473-4480.	3.6	25
224	Obesity and Ovarian Cancer Survival: A Systematic Review and Meta-analysis. Cancer Prevention Research, 2012, 5, 901-910.	1.5	121
225	Correction: <i>ABCB1 (MDR1)</i> Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2012, 18, 319-320.	7.0	2
226	Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal of Epidemiology, 2012, 176, 269-278.	3.4	76
227	InterSCOPE Study: Associations Between Esophageal Squamous Cell Carcinoma and Human Papillomavirus Serological Markers. Journal of the National Cancer Institute, 2012, 104, 147-158.	6.3	71
228	Estimated intake of dietary phyto-oestrogens in Australian women and evaluation of correlates of phyto-oestrogen intake. Journal of Nutritional Science, 2012, 1, e11.	1.9	5
229	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	10.7	753
230	Intake of omega-3 and omega-6 fatty acids and risk of ovarian cancer. Cancer Causes and Control, 2012, 23, 1775-1783.	1.8	19
231	The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiology, 2012, 36, 306-316.	1.9	65
232	Ovarian cancer and smoking: individual participant meta-analysis including 28â€^114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncology, The, 2012, 13, 946-956.	10.7	125
233	<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in ⟨i⟩BRCA Mutationâ€"Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 2654-2663.	1.6	1,018
234	<i>Helicobacter pylori</i> infection and the risks of Barrett's oesophagus: A populationâ€based caseâ€"control study. International Journal of Cancer, 2012, 130, 2407-2416.	5.1	51

#	Article	IF	CITATIONS
235	Body mass index, longâ€ŧerm weight change, and esophageal squamous cell carcinoma. Cancer, 2012, 118, 1901-1909.	4.1	41
236	Use of talcum powder and endometrial cancer risk. Cancer Causes and Control, 2012, 23, 513-519.	1.8	17
237	Lifetime Alcohol Consumption and Risk of Barrett's Esophagus. American Journal of Gastroenterology, 2011, 106, 1220-1230.	0.4	29
238	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertility and Sterility, 2011, 95, 40-45.	1.0	20
239	The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Alimentary Pharmacology and Therapeutics, 2011, 34, 1235-1244.	3.7	28
240	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics, 2011, 43, 451-454.	21.4	141
241	Gynecological conditions and the risk of endometrial cancer. Gynecologic Oncology, 2011, 123, 537-541.	1.4	58
242	Loss of lifestyle: health behaviour and weight changes after becoming a caregiver of a family member diagnosed with ovarian cancer. Supportive Care in Cancer, 2011, 19, 1949-1956.	2.2	98
243	Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. BMC Cancer, 2011, 11, 389.	2.6	53
244	The Working After Cancer Study (WACS): a population-based study of middle-aged workers diagnosed with colorectal cancer and their return to work experiences. BMC Public Health, 2011, 11, 604.	2.9	17
245	Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psycho-Oncology, 2011, 20, 1161-1169.	2.3	36
246	Xenobioticâ€Metabolizing gene polymorphisms and ovarian cancer risk. Molecular Carcinogenesis, 2011, 50, 397-402.	2.7	29
247	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	2.9	22
248	Population Attributable Fractions of Adenocarcinoma of the Esophagus and Gastroesophageal Junction. American Journal of Epidemiology, 2011, 174, 582-590.	3.4	61
249	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1028-1031.	2.5	0
250	Carbohydrate intake, glycemic load, glycemic index, and risk of ovarian cancer. Annals of Oncology, 2011, 22, 1332-1338.	1.2	28
251	CHEK2, MGMT, SULT1E1 and SULT1A1 Polymorphisms and Endometrial Cancer Risk. Twin Research and Human Genetics, 2011, 14, 328-332.	0.6	12
252	High Intake of Folate from Food Sources Is Associated with Reduced Risk of Esophageal Cancer in an Australian Population,. Journal of Nutrition, 2011, 141, 274-283.	2.9	56

#	Article	IF	CITATIONS
253	Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2011, 29, 2253-2258.	1.6	52
254	Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer. European Journal of Clinical Nutrition, 2011, 65, 1133-1140.	2.9	34
255	Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis, 2011, 32, 331-335.	2.8	22
256	The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in Non-Hispanic White Women. PLoS ONE, 2011, 6, e16756.	2.5	58
257	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642.	2.5	5
258	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	2.5	21
259	Season of birth and risk of endometrial cancer. Asian Pacific Journal of Cancer Prevention, 2011, 12, 1193-6.	1.2	7
260	Medical Costs and Outcomes for Australian Women With Ovarian Cancer: A Patient-Level Analysis Over 2.5 Years. International Journal of Gynecological Cancer, 2010, 20, 757-765.	2.5	19
261	Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer, 2010, 18, 943-949.	2.2	8
262	Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes and Control, 2010, 21, 109-116.	1.8	61
263	Tea consumption and risk of ovarian cancer. Cancer Causes and Control, 2010, 21, 1485-1491.	1.8	42
264	Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50Âyears: an Australian case–control study. Cancer Causes and Control, 2010, 21, 2303-2308.	1.8	131
265	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
266	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
267	Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Medical Journal of Australia, 2010, 193, S52-7.	1.7	82
268	Pathways to the diagnosis of epithelial ovarian cancer in Australia. Medical Journal of Australia, 2010, 193, 326-330.	1.7	17
269	Meat, fish, and ovarian cancer risk: results from 2 Australian case-control studies, a systematic review, and meta-analysis. American Journal of Clinical Nutrition, 2010, 91, 1752-1763.	4.7	62
270	Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 600-604.	2.5	23

#	Article	IF	CITATIONS
271	Cigarette Smoking and Adenocarcinomas of the Esophagus and Esophagogastric Junction: A Pooled Analysis From the International BEACON Consortium. Journal of the National Cancer Institute, 2010, 102, 1344-1353.	6.3	259
272	Genetic Variation in <i>TYMS</i> in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1822-1830.	2.5	24
273	KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population. American Journal of Gastroenterology, 2010, 105, 2209-2217.	0.4	59
274	Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?. Gut, 2010, 59, 31-38.	12.1	49
275	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility "Hot-Spot― PLoS Genetics, 2010, 6, e1001016.	3.5	48
276	<i>ESR1/SYNE1</i> Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 245-250.	2.5	75
277	Re: Predictive Value of Symptoms for Early Detection of Ovarian Cancer. Journal of the National Cancer Institute, 2010, 102, 1599-1601.	6.3	4
278	Hyperplastic Polyposis Syndrome Is Associated With Cigarette Smoking, Which May Be a Modifiable Risk Factor. American Journal of Gastroenterology, 2010, 105, 1642-1647.	0.4	32
279	Association of Helicobacter pylori Infection With Reduced Risk for Esophageal Cancer Is Independent of Environmental and Genetic Modifiers. Gastroenterology, 2010, 139, 73-83.	1.3	114
280	Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: A pooled analysis. European Journal of Cancer, 2010, 46, 2067-2076.	2.8	71
281	Does type 2 diabetes influence the risk of oesophageal adenocarcinoma?. British Journal of Cancer, 2009, 100, 795-798.	6.4	42
282	Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. Twin Research and Human Genetics, 2009, 12, 269-275.	0.6	8
283	Reproducibility of food and nutrient intake estimates using a semi-quantitative FFQ in Australian adults. Public Health Nutrition, 2009, 12, 2359-2365.	2.2	65
284	Beyond Parity: Association of Ovarian Cancer With Length of Gestation and Offspring Characteristics. American Journal of Epidemiology, 2009, 170, 607-614.	3.4	18
285	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Human Molecular Genetics, 2009, 18, 2297-2304.	2.9	42
286	Dietary patterns and ovarian cancer risk. American Journal of Clinical Nutrition, 2009, 89, 297-304.	4.7	45
287	Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 2349-2357.	0.9	63
288	Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer, 2009, 9, 378.	2.6	41

#	Article	IF	CITATIONS
289	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
290	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British Journal of Cancer, 2009, 100, 412-420.	6.4	47
291	Do low control response rates always affect the findings? Assessments of smoking and obesity in two Australian caseâ€control studies of cancer. Australian and New Zealand Journal of Public Health, 2009, 33, 312-319.	1.8	38
292	The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: An Australian study and systematic review. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2009, 49, 316-322.	1.0	43
293	Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer. American Journal of Human Genetics, 2009, 85, 427-446.	6.2	165
294	Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 2009, 45, 3262-3270.	2.8	48
295	Alcohol Consumption and the Risks of Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus. Gastroenterology, 2009, 136, 1215-1224.e2.	1.3	153
296	Current and Past Smoking Significantly Increase Risk for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2009, 7, 840-848.	4.4	53
297	Fertility drugs and ovarian cancer. BMJ: British Medical Journal, 2009, 338, a3075-a3075.	2.3	3
298	Serous ovarian, fallopian tube and primary peritoneal cancers: A comparative epidemiological analysis. International Journal of Cancer, 2008, 122, 1598-1603.	5.1	91
299	Cancers of the esophagus and carbonated beverage consumption: a population-based case–control study. Cancer Causes and Control, 2008, 19, 577-584.	1.8	23
300	Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. International Journal of Cancer, 2008, 122, 170-176.	5.1	205
301	Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. International Journal of Cancer, 2008, 123, 174-180.	5.1	65
302	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	5.1	73
303	Body size and risk of epithelial ovarian and related cancers: A populationâ€based caseâ€control study. International Journal of Cancer, 2008, 123, 450-456.	5.1	49
304	Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. British Journal of Cancer, 2008, 98, 282-288.	6.4	49
305	The influence of reproductive and hormonal factors on ovarian cancer survival. International Journal of Gynecological Cancer, 2008, 18, 407-413.	2.5	33
306	Vitamin D for prevention of chronic disease: the need for continued research. Internal Medicine Journal, 2008, 38, 813-815.	0.8	5

#	Article	IF	CITATIONS
307	Re: Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecologic Oncology, 2008, 109, 153.	1.4	7
308	Endometrioid and clear cell ovarian cancers $\hat{a} \in A$ comparative analysis of risk factors. European Journal of Cancer, 2008, 44, 2477-2484.	2.8	82
309	Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23â€^257 women with ovarian cancer and 87â€^303 controls. Lancet, The, 2008, 371, 303-314.	13.7	690
310	Variation in bone morphogenetic protein 15 is not associated with spontaneous human dizygotic twinning. Human Reproduction, 2008, 23, 2372-2379.	0.9	32
311	Associations of Duration, Intensity, and Quantity of Smoking with Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus. American Journal of Epidemiology, 2008, 168, 105-114.	3.4	89
312	Single Nucleotide Polymorphisms in Obesity-Related Genes and the Risk of Esophageal Cancers. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1007-1012.	2.5	41
313	<i>ABCB1</i> (<i>MDR 1</i>) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2008, 14, 5594-5601.	7.0	90
314	ATG16L1 T300A Shows Strong Associations With Disease Subgroups in a Large Australian IBD Population: Further Support for Significant Disease Heterogeneity. American Journal of Gastroenterology, 2008, 103, 2519-2526.	0.4	79
315	Epithelial ovarian cancer: testing the 'androgens hypothesis'. Endocrine-Related Cancer, 2008, 15, 1061-1068.	3.1	78
316	Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1169-1178.	2.5	77
317	Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut, 2008, 57, 173-180.	12.1	259
318	Polymorphism in the <i>IL18</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3567-3572.	2.5	18
319	Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2557-2565.	2.5	65
320	Microarrays and Epidemiology: Not the Beginning of the End but the End of the Beginning…. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 637-638.	2.5	9
321	Leptin and the risk of Barrett's oesophagus. Gut, 2007, 57, 448-454.	12.1	126
322	Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2007, 67, 3027-3035.	0.9	78
323	Recreational Physical Activity and Epithelial Ovarian Cancer: A Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2321-2330.	2.5	92
324	Risk Factors for Benign Serous and Mucinous Epithelial Ovarian Tumors. Obstetrics and Gynecology, 2007, 109, 647-654.	2.4	26

#	Article	IF	Citations
325	The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. European Journal of Cancer, 2007, 43, 283-290.	2.8	40
326	Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer, 2007, 43, 690-709.	2.8	255
327	Health effects of recreational exposure to Moreton Bay, Australia waters during a Lyngbya majuscula bloom. Environment International, 2007, 33, 309-314.	10.0	41
328	Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes. Cancer Letters, 2007, 251, 96-104.	7.2	12
329	Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum?. Gynecologic Oncology, 2007, 107, 223-230.	1.4	70
330	The MnSOD Val9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia). Gynecologic Oncology, 2007, 107, 388-391.	1.4	15
331	Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. European Journal of Gynaecological Oncology (discontinued), 2007, 28, 376-80.	0.2	8
332	Novel Variants in Growth Differentiation Factor 9 in Mothers of Dizygotic Twins. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4713-4716.	3.6	121
333	Recreational and occupational field exposure to freshwater cyanobacteria – a review of anecdotal and case reports, epidemiological studies and the challenges for epidemiologic assessment. Environmental Health, 2006, 5, 6.	4.0	133
334	Cutaneous hypersensitivity reactions to freshwater cyanobacteria – human volunteer studies. BMC Dermatology, 2006, 6, 6.	2.1	30
335	Stool antigen testing for the diagnosis and confirmation of eradication of Helicobacter pylori infection. Internal Medicine Journal, 2006, 36, 139-141.	0.8	1
336	Benign Epithelial Ovarian Tumoursâ€"cancer Precursors or Markers for Ovarian Cancer Risk?. Cancer Causes and Control, 2006, 17, 623-632.	1.8	28
337	Does smoking increase risk of ovarian cancer? A systematic review. Gynecologic Oncology, 2006, 103, 1122-1129.	1.4	104
338	Epidemiology of recreational exposure to freshwater cyanobacteria – an international prospective cohort study. BMC Public Health, 2006, 6, 93.	2.9	73
339	Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 875-883.	5.1	24
340	Commentary: Weight gain, weight loss, and endometrial cancer. International Journal of Epidemiology, 2006, 35, 166-168.	1.9	20
341	Cigarette Smoking and Survival after Ovarian Cancer Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2557-2560.	2.5	31
342	Searching for cancer deaths in Australia: National Death Index vs. cancer registries. Asian Pacific Journal of Cancer Prevention, 2006, 7, 41-5.	1,2	8

#	Article	IF	CITATIONS
343	Repeatability of self-reported information for population-based studies of cancer. Asian Pacific Journal of Cancer Prevention, 2006, 7, 303-8.	1.2	7
344	Height, Age at Menarche, and Risk of Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2045-2048.	2.5	39
345	Interactions among Smoking, Obesity, and Symptoms of Acid Reflux in Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2481-2486.	2.5	118
346	Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 319-323.	2.5	77
347	Mathematical Models of Ovarian Cancer Incidence. Epidemiology, 2005, 16, 508-515.	2.7	40
348	Recurrence of Helicobacter pyloriin fection in adults with intellectual disability. Internal Medicine Journal, 2004, 34, 132-133.	0.8	14
349	A Review of the Risk Factors for, Consequences, Diagnosis, and Management of Helicobacter pylori in Adults with Intellectual Disabilities. Journal of Policy and Practice in Intellectual Disabilities, 2004, 1, 147-163.	2.7	8
350	Effects of Helicobacter pylori eradication among adults with intellectual disability. Journal of Intellectual Disability Research, 2004, 48, 646-654.	2.0	20
351	Changes in survival after breast cancer: improvements in diagnosis or treatment?. Breast, 2004, 13, 7-14.	2.2	40
352	Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecologic Oncology, 2004, 92, 232-239.	1.4	77
353	Coffee, Tea and Caffeine and Risk of Epithelial Ovarian Cancer. Cancer Causes and Control, 2004, 15, 359-365.	1.8	51
354	Alcohol, wine, and risk of epithelial ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 592-9.	2.5	17
355	A prospective study of diet and benign breast disease. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1106-13.	2.5	14
356	The Different Etiologies of Mucinous and Nonmucinous Epithelial Ovarian Cancers. Gynecologic Oncology, 2003, 88, S145-S148.	1.4	49
357	Ovulation and risk of epithelial ovarian cancer. International Journal of Cancer, 2003, 104, 228-232.	5.1	156
358	Dietary influences on survival after ovarian cancer. International Journal of Cancer, 2003, 106, 264-269.	5.1	94
359	Diagnosis of Helicobacter pylori Infection in Adults with Intellectual Disability. Journal of Clinical Microbiology, 2003, 41, 4700-4704.	3.9	20
360	National ethics committee urgently needed. Medical Journal of Australia, 2003, 178, 187-187.	1.7	9

#	Article	IF	CITATIONS
361	Environmental, medical, behavioural and disability factors associated with Helicobacter pylori infection in adults with intellectual disability. Journal of Intellectual Disability Research, 2002, 46, 51-60.	2.0	44
362	Family history of breast cancer, age and benign breast disease. International Journal of Cancer, 2002, 100, 375-378.	5.1	36
363	The toxins of Lyngbya majuscula and their human and ecological health effects. Environment International, 2001, 27, 381-392.	10.0	214
364	The microsomal epoxide hydrolase Tyr113His polymorphism: Association with risk of ovarian cancer. Molecular Carcinogenesis, 2001, 30, 71-78.	2.7	36
365	Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes and Control, 2001, 12, 713-719.	1.8	51
366	Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes and Control, 2001, 12, 855-863.	1.8	87
367	Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis, 2001, 22, 67-72.	2.8	73
368	Reproduction-related Risk Factors for Mucinous and Nonmucinous Epithelial Ovarian Cancer. American Journal of Epidemiology, 2001, 153, 860-864.	3.4	50
369	No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis, 2001, 22, 717-721.	2.8	35
370	Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut, 2001, 49, 347-353.	12.1	897
371	CYP17 promotor polymorphism and ovarian cancer risk., 2000, 86, 436-439.		35
372	Androgen receptor exon 1 cag repeat length and risk of ovarian cancer. International Journal of Cancer, 2000, 87, 637-643.	5.1	37
373	Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. International Journal of Cancer, 2000, 87, 637-43.	5.1	7
374	Gastric cancer, cytotoxin-associated gene A–positive Helicobacter pylori, and serum pepsinogens: An international study. Gastroenterology, 1999, 116, 269-276.	1.3	89
375	Milk consumption, galactose metabolism and ovarian cancer (Australia). Cancer Causes and Control, 1998, 9, 637-644.	1.8	48
376	Relationship Between Number of Ovulatory Cycles and Accumulation of Mutant p53 in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 1998, 90, 1729-1734.	6.3	41
377	Gastric cancer, gastritis and plasma vitamin C: Results from an international correlation and cross-sectional study., 1997, 73, 684-689.		31
378	Is Helicobacter pylori Transmitted from Cats to Humans?. Helicobacter, 1996, 1, 79-81.	3.5	23

#	Article	IF	CITATIONS
379	An apparent lack of association betweenHelicobacter pylori infection and risk of gastric cancer in China., 1996, 67, 603-607.		69
380	Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high-risk groups. British Journal of Cancer, 1996, 73, 819-824.	6.4	57
381	Helicobacter pylori transmission: evidence from a comparison with hepatitis A virus. European Journal of Gastroenterology and Hepatology, 1996, 8, 439-41.	1.6	17
382	9 Helicobacter pylori as a risk factor for cancer. Bailliere's Clinical Gastroenterology, 1995, 9, 563-582.	0.9	47
383	H pylori and gastric cancer. Lancet, The, 1994, 343, 243-244.	13.7	227
384	The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. Gastroenterology, 1994, 107, 1335-1344.	1.3	57
385	Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life. BMJ: British Medical Journal, 1994, 308, 750-753.	2.3	312
386	Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. The EUROGAST Study Group Gut, 1993, 34, 1672-1676.	12.1	382